Cart summary

You have no items in your shopping cart.

Favipiravir

SKU: orb1300424

Description

Favipiravir is a selective inhibitor of viral RNA-dependent RNA polymerase, developed for influenza research. It is used in both in vitro and in vivo studies to investigate antiviral mechanisms and efficacy against influenza virus infections.

Research Area

Cell Biology, Infectious Disease & Virology, Molecular Biology

Images & Validation

−
Favipiravir

Key Properties

−
CAS Number259793-96-9
MW157.1
Purity>99.99% (May vary between batches)
FormulaC5H4FN3O2
SMILESNC(=O)c1nc(F)cnc1O
TargetAntibacterial,Influenza Virus,DNA/RNA Synthesis,SARS-CoV
SolubilityDMSO:126 mg/mL (802.04 mM);H2O:5 mg/mL (31.83 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (25.46 mM);Ethanol:12 mg/mL (76.38 mM)

Bioactivity

−
Target IC50
RdRP:341 nM.
In Vivo
METHODS: When Favipiravir (T-705) is used at a dose of 1-100mg/kg and infected with a lethal dose of influenza virus A/Victoria/3/75 (H3N2), A/Osaka/5/70 (H3N2) or A/ Duck/MN/1525/81 (H5N1) was administered orally 2 or 4 times a day to mice for 5 days, and the survival rate of the mice was observed. RESULTS Favipiravir (T-705) showed improved survival compared with placebo at doses of 30 mg/kg/day or higher, the drug was also administered at doses of 33 mg/kg/day or higher Provides significant protection against A/Duck/MN/1525/81 (H5N1) virus. METHODS: Favipiravir was administered at 120 mg/kg/day or 200 mg/kg/day on days 1-5 after lethal SFTSV infection in type I interferon receptor knockout (IFNAR −/−) mice. (T-705) and continued for 5 days to observe the growth status of the mice. RESULTS All favipiravir-treated mice at doses of 120 mg/kg/day or 200 mg/kg/day, respectively, survived lethal SFTSV infection when treatment was initiated within 3 and 4 days of infection.
Read more...
In Vitro
METHODS: RAW 264.7 cells were infected with MNV at an MOI of 0,001 using a T-705 dilution series (3.13-200 lg/mL). The MTS CPE reduction method was used to determine the antiviral activity of T-705 in the MNV/RAW 264.7 cell line. After 3 days of incubation, complete CPE was observed in the infected untreated cells. The cell culture supernatant was collected and analyzed by quantitative RT- PCR (qRT-PCR) quantitatively detects viral RNA load. RESULTS T-705 inhibited MNV-induced CPE (EC50: 39 ± 4 lg/mL [250 ± 11 lM]) and MNV RNA synthesis in cell culture (EC50: 19 ± 6 lg/mL [124 ± 42 lM]).
Read more...
Cell Research
The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 103 cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO2. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).(Only for Reference)
Read more...

Storage & Handling

−
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

−
T 705, T705, T-705, SARS coronavirus, SARSCoV, SARS-CoV, RNA Synthesis, RNA-dependent RNA polymerase, RNASynthesis, inhibit, InfluenzaVirus, Influenza Virus, Inhibitor, Favipiravir, DNASynthesis, DNA/RNA Synthesis, DNA Synthesis, 6-Fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide

Similar Products

−
  • T-705RMP ammonium

    T-705RMP ammonium [orb2565200]

    2096342-42-4

    386.23

    C10H16FN4O9P

    50 mg, 10 mg
  • T-705RMP

    T-705RMP [orb1690583]

    356783-08-9

    369.20

    C10H13FN3O9P

    25 mg
  • Favipiravir sodium

    Favipiravir sodium [orb1738625]

    1366418-99-6

    180.09

    C5H4FN3NaO2+

    50 mg, 25 mg, 100 mg
  • Favipiravir

    Favipiravir [orb1225488]

    >98% (HPLC)

    259793-96-9

    157.1

    C5H4FN3O2

    10 mg, 50 mg, 500 mg, 1 g, 100 mg, 5 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Compound Identifiers

PubChem CID
492405 ↗

Key Properties

−
No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Find More Protocols

Favipiravir (orb1300424)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Login to review

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

1 ml x 10 mM (in DMSO)
$ 90.00
5 mg
$ 90.00
10 mg
$ 100.00
50 mg
$ 130.00
100 mg
$ 170.00
500 mg
$ 360.00
DispatchUsually dispatched within 3-5 working days
Bulk Enquiry
Need technical support? Find your Distributor Return and Tax Policy

Email

info@biorbyt.com

UK Office

+44 (0)1223 859353

US Office

+1 (415) 906-5211

CN Office

+86 (27)-87663101

Distributors

biorbyt.com/distributor